{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dmards/management/tofacitinib/","result":{"pageContext":{"chapter":{"id":"1dcd6206-8d6f-548c-a253-fc19d5deb6e7","slug":"tofacitinib","fullItemName":"Scenario: Tofacitinib","depth":2,"htmlHeader":"<!-- begin field d634e787-d71d-416a-9d77-a7ee00a534fe --><h2>Scenario: Tofacitinib</h2><!-- end field d634e787-d71d-416a-9d77-a7ee00a534fe -->","summary":"Covers the monitoring of tofacitinib in adults in primary care.","htmlStringContent":"<!-- begin item 168a595f-a27d-43c7-94f3-a7ee00a5336b --><!-- begin field 545a6861-f9db-4080-a083-acbc015c27aa --><p>From age 18 years onwards.</p><!-- end field 545a6861-f9db-4080-a083-acbc015c27aa --><!-- end item 168a595f-a27d-43c7-94f3-a7ee00a5336b -->","topic":{"id":"493980c0-c660-5bda-b643-f98644c1eff8","topicId":"caed8aa7-f8ba-4a46-9441-92701c2ad78a","topicName":"DMARDs","slug":"dmards","lastRevised":"Last revised in April 2020","chapters":[{"id":"d587cd65-a186-50e3-a192-8d3f3b5c074b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e4b02852-ea41-536a-8ec9-462ecfc95b24","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"189d2086-77a0-57a3-84ed-6f44f1e56879","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ff583a6c-57af-5ded-8488-19039e0cd272","slug":"changes","fullItemName":"Changes"},{"id":"d65ec114-ec65-504e-a69b-b4fef29f3ca6","slug":"update","fullItemName":"Update"}]},{"id":"c02019ed-342b-5aa7-a645-a8c979fa0d56","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0ee8d208-7733-5a7d-928a-41e080d05756","slug":"goals","fullItemName":"Goals"},{"id":"2206fe89-030d-5fec-adf5-ee4a379ff3a0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca18e3ee-b448-5d95-b060-d5ab2e909dd2","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ce5c5664-0c85-52e9-b3d1-835fa7e52c8f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ac9bf99d-b5d4-5d63-8e5c-bb174916417e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2c23a774-3e76-52d5-8316-b8cbe2060151","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"33f76ef2-b579-5b80-985a-587d2f7cbb17","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13df5021-0440-5dfe-b200-6910e116b50b","slug":"indications","fullItemName":"Indications"}]},{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","fullItemName":"Management","slug":"management","subChapters":[{"id":"a22ece65-e42d-59b8-82a9-4633e64a7441","slug":"general-principles-of-managing-dmards","fullItemName":"Scenario: General principles of managing DMARDs"},{"id":"7428c7c0-3189-5d82-8d3c-61151fc43773","slug":"apremilast","fullItemName":"Scenario: Apremilast"},{"id":"c241c22b-6dd4-5334-b240-a532f0f78fd7","slug":"azathioprine","fullItemName":"Scenario: Azathioprine"},{"id":"cff5fc6d-3554-5bf8-832a-c8a089699b6f","slug":"baricitinib","fullItemName":"Scenario: Baricitinib"},{"id":"fc4f9786-0db2-5fcd-a2ca-589807093e6a","slug":"biologics","fullItemName":"Scenario: Biologics"},{"id":"a8c361a4-0693-5e57-a935-24a8383a76ba","slug":"ciclosporin","fullItemName":"Scenario: Ciclosporin"},{"id":"92b93974-10b7-5147-b0cb-e21d187093e4","slug":"cyclophosphamide","fullItemName":"Scenario: Cyclophosphamide"},{"id":"928496d4-4642-55d5-98fe-86bd350c2913","slug":"gold-intramuscular","fullItemName":"Scenario: Gold - intramuscular"},{"id":"bed27174-d641-5a3b-958e-fdb3f1b0c33f","slug":"hydroxychloroquine","fullItemName":"Scenario: Hydroxychloroquine"},{"id":"b87df30d-4917-58a4-84b5-2db454410a88","slug":"leflunomide","fullItemName":"Scenario: Leflunomide"},{"id":"29f64422-8646-5cd9-ab79-c6919331e041","slug":"methotrexate","fullItemName":"Scenario: Methotrexate"},{"id":"c4758020-9fa5-5122-9cd7-c871ebd54d73","slug":"mycophenolate-mofetil-mmf","fullItemName":"Scenario: Mycophenolate mofetil (MMF)"},{"id":"5870b3d5-8b5b-5029-86fa-0f688b740005","slug":"penicillamine","fullItemName":"Scenario: Penicillamine"},{"id":"7b2bca14-9fd5-55c7-9a3f-bb044a5c53cb","slug":"sulfasalazine","fullItemName":"Scenario: Sulfasalazine"},{"id":"4fddf07b-12b6-51d6-93db-59bb536a2db1","slug":"tacrolimus","fullItemName":"Scenario: Tacrolimus"},{"id":"1dcd6206-8d6f-548c-a253-fc19d5deb6e7","slug":"tofacitinib","fullItemName":"Scenario: Tofacitinib"},{"id":"6e4b7cba-f4a1-5221-9b40-b3adeaf750bc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"0fcf14f9-de6c-5f14-b7e2-222e952f6aa4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5bcf1ebc-c823-5866-8643-bb3a12bd2e78","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"99f1248a-29fc-5534-8f2a-306820d31914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92a3e377-bfa8-5bcb-92d5-38bd17e970e8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2fda74-5193-58b7-9e0b-40e6129a4629","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"65080272-e93d-5ccb-a5f0-bcecaca6aae1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"44895091-401a-5a9b-b11f-a4e952ec6de2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"caffbaca-bd54-566b-921b-c2363a59a842","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"8f5fa259-d31d-5166-be0b-20174d47e89f","slug":"tofacitinib-monitoring-requirements","fullItemName":"Tofacitinib monitoring requirements","depth":3,"htmlHeader":"<!-- begin field e03396bb-4847-49f0-90c7-a7ee00a53503 --><h3>What monitoring is required for tofacitinib?</h3><!-- end field e03396bb-4847-49f0-90c7-a7ee00a53503 -->","summary":null,"htmlStringContent":"<!-- begin item 9a926365-8544-450c-a9b6-a7ee00a53503 --><!-- begin field 4103d2e6-b2de-4fb8-bece-a7ee00a53503 --><ul><li>Prescribing of tofacitinib will usually be part of a shared-care protocol. Follow the recommendations of local guidelines where they differ from those given below. Whilst absolute values are useful indicators, trends are equally important, and any rapid fall or consistent downward trend in any parameter warrants extra vigilance.</li><li>People who are starting treatment with a tofacitinib should be screened for active and latent tuberculosis (TB) before starting treatment. In addition, they should be monitored closely for infectious diseases including TB before, during, and after treatment for six months.</li><li>The manufacturer advises that tofacitinib is contra-indicated in patients with risk factors for pulmonary embolism.</li><li>For information on when to refer people on tofacitinib, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/dmards/management/general-principles-of-managing-dmards/#when-to-refer\">when to refer</a>.</li></ul><p><strong>Table 13.</strong> Primary care monitoring requirements for people on tofacitinib.</p><table><thead><tr><th scope=\"col\">Monitoring</th><th scope=\"col\">Frequency</th></tr></thead><tbody><tr><td colspan=\"1\">Full Blood Count (FBC)</td><td colspan=\"1\" rowspan=\"3\"><ul><li>Every 2 weeks until dose is stable for 6 weeks. </li><li>Then monthly for 3 months. </li><li>Thereafter, at least every 12 weeks.<ul><li>More frequent monitoring is appropriate in patients at higher risk of toxicity.</li></ul></li><li><strong>Dose increases:</strong> Every 2 weeks until dose is stable for 6 weeks, then revert to previous schedule.</li></ul></td></tr><tr><td colspan=\"1\">Creatinine/calculated GFR<sup>*</sup></td></tr><tr><td colspan=\"1\">Liver Function Tests (LFTs): ALT and/or AST and albumin.</td></tr><tr><td>Lipid profile</td><td><ul><li>Monitor lipids 8 weeks after treatment started, then monitor periodically.<ul><li>Hyperlipidaemia should be managed according to clinical guidelines.</li></ul></li></ul></td></tr><tr><td>Tuberculosis</td><td><ul><li>If clinically indicated.</li></ul></td></tr><tr><td colspan=\"2\">AST, aspartate transaminase; ALT, alanine aminotransferase. *This has been extrapolated from the monitoring requirements for other non-biologic DMARDs</td></tr><tr><td colspan=\"2\"><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ACR, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BSR, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017r</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BNF 73, 2017</a>]</td></tr></tbody></table><!-- end field 4103d2e6-b2de-4fb8-bece-a7ee00a53503 --><!-- end item 9a926365-8544-450c-a9b6-a7ee00a53503 -->","subChapters":[{"id":"0e880b36-b896-5361-8a5a-9f33f06c8bc2","slug":"basis-for-recommendation-df2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 794830e7-55cf-4e64-89f5-a7ee00a5350c --><h4>Basis for recommendation</h4><!-- end field 794830e7-55cf-4e64-89f5-a7ee00a5350c -->","summary":null,"htmlStringContent":"<!-- begin item df29825b-4a74-4b33-9f84-a7ee00a5350c --><!-- begin field 478a33fe-cc61-4cc3-b602-a7ee00a5350c --><p>These recommendations are based on the manufacturer's Summary of Product Characteristics for tofacitinib [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017c</a>], the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BNF 73, 2017</a>], the American College of Rheumatology (ACR) <em>Guideline for the treatment of rheumatoid arthritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ACR, 2015</a>], and extrapolated from the British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) <em>BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BSR, 2017</a>], which details requirements for other non-biologic DMARDs.</p><h5>Creatinine/GFR</h5><ul><li>CKS could find no specific guidance to indicate that creatinine/GFR needs to be monitored. This is a pragmatic recommendation, based on what Prodgy consider good clinical practice.</li></ul><h5>Tuberculosis (TB) screening</h5><ul><li>The same TB screening algorithm used for biologic DMARDs should be used for tofacitinib [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ACR, 2015</a>].</li></ul><h5>Frequency of monitoring</h5><ul><li>The manufacturer's Summary of Product Characteristics advises the following monitoring frequency:<ul><li>Lymphocytes at baseline and every 3 months thereafter.</li><li>Neutrophils and haemoglobin at baseline, after 4-8 weeks of treatment, and every 3 months thereafter [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017r</a>].</li></ul></li><li>However, CKS considers that the initial monitoring frequency for other non-biologic DMARDs may be appropriate for tofacitinib.<ul><li>Local shared care agreements should be followed if they differ.</li></ul></li></ul><!-- end field 478a33fe-cc61-4cc3-b602-a7ee00a5350c --><!-- end item df29825b-4a74-4b33-9f84-a7ee00a5350c -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}